FIGURE

Fig. 7

ID

ZDB-FIG-241206-7

Publication

Smith et al., 2024 - Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment

Other Figures

All Figure Page

Back to All Figure Page

Fig. 7

Lenvatinib halts AM tumor growth or induces regression by remodeling tumor vasculature. A Representative histology (H&E, 10 × objective) and immunohistochemistry (IHC) images of vehicle and Lenvatinib HCI-AM087 are shown. CD31 (20x objective) and transferrin receptor 1 (TfR1, 40x objective) were stained with DAB, and MiB/Ki67 (10x objective) was stained with red chromogen. Scale bars are in microns. A pathologist quantified the B Ki67 IHC positive cell percentage, C percent necrosis from H&E-stained sections, D membranous TfR1 IHC scores, and E CD31 positive IHC vessels. Significance was determined using the Student’s t-test. F While CM has reduced tumor proliferation and diminished blood vessel quantity and quality on Lenvatinib therapy, these PDX tumors often continue to grow. There are no observed direct cytotoxic effects of Lenvatinib on AM cells. Instead, tumor regression or stable disease is achieved in AM tumors by reducing the blood vessel quantity and quality

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Clin. Cancer Res.